We are at a critical crossroads for the clinical use of ctDNA in early-stage breast cancer, according to Dr. Heather A. Parsons. “What if we could reliably identify molecular re ...

Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a precision diagnostics company, today announced that it has in-licensed from ...